|
US7658924B2
(en)
|
2001-10-11 |
2010-02-09 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
|
US9200061B2
(en)
|
2004-02-06 |
2015-12-01 |
Morpho Sys AG |
Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
|
|
BRPI0507489A
(pt)
*
|
2004-02-06 |
2007-07-10 |
Morphosys Ag |
anticorpos humanos de anti-cd38 e para os seus usos
|
|
SI2511297T1
(sl)
|
2004-02-06 |
2015-07-31 |
Morphosys Ag |
Proti -CD38 humana protitelesa in njihova uporaba
|
|
IL316252A
(en)
|
2005-03-23 |
2024-12-01 |
Genmab As |
Antibodies against cd38 for treatment of multiple myeloma
|
|
SG10201400973XA
(en)
|
2005-10-12 |
2014-08-28 |
Morphosys Ag |
Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
|
|
EA019476B9
(ru)
|
2005-12-29 |
2020-07-14 |
Янссен Байотек, Инк. |
АНТИТЕЛА ПРОТИВ IL-23p19 И ИХ ПРИМЕНЕНИЕ
|
|
WO2007142241A1
(ja)
*
|
2006-06-05 |
2007-12-13 |
Hiroshima University |
抗ｃｄ３８抗体を細胞表面に有する免疫担当細胞
|
|
EP3753576A1
(en)
*
|
2006-09-26 |
2020-12-23 |
Genmab A/S |
Combination treatment of cd38-expressing tumors
|
|
EP1914242A1
(en)
*
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
|
AU2013209322A1
(en)
*
|
2006-10-19 |
2013-08-15 |
Sanofi-Aventis |
Novel anti-cd38 antibodies for the treatment of cancer
|
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
|
EP2191840A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
|
|
EP2191841A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
|
|
WO2010079189A1
(en)
|
2009-01-09 |
2010-07-15 |
Morphosys Ag |
Display vectors and methods and uses thereof
|
|
PT2580243T
(pt)
|
2010-06-09 |
2020-01-22 |
Genmab As |
Anticorpos contra cd38 humana
|
|
LT2621531T
(lt)
|
2010-09-27 |
2017-04-10 |
Morphosys Ag |
Anti-cd38 antikūnas ir lenalidomidas arba bortezomibas, skirti išsėtinės mielomos ir nhl (nehodžino limfoma) gydymui
|
|
EP2625205A2
(en)
*
|
2010-10-05 |
2013-08-14 |
Daiichi Sankyo Company, Limited |
Antibody targeting osteoclast-related protein siglec-15
|
|
UA112170C2
(uk)
|
2010-12-10 |
2016-08-10 |
Санофі |
Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
EA034989B1
(ru)
|
2011-10-28 |
2020-04-15 |
Тева Фармасьютикал Австралия Пти Лтд |
Полипептидная конструкция для применения при лечении рака, включающая аттенуированный альфа-интерферон
|
|
US9579378B2
(en)
|
2012-09-25 |
2017-02-28 |
Morphosys Ag |
Combinations and uses thereof
|
|
DK2914302T3
(en)
|
2012-11-05 |
2017-04-10 |
Morphosys Ag |
RADIOACTIVALLY MARKED ANTIBODY AND USES OF IT
|
|
JP2014117191A
(ja)
*
|
2012-12-13 |
2014-06-30 |
Fisheries Research Agency |
リン酸化中性スフィンゴミエリナーゼ１、抗リン酸化中性スフィンゴミエリナーゼ１抗体、中性スフィンゴミエリナーゼ１変異体、及びそれらの用途
|
|
KR102391731B1
(ko)
|
2013-01-14 |
2022-04-27 |
젠코어 인코포레이티드 |
신규한 이형이량체 단백질
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
DK3677591T5
(da)
*
|
2013-04-29 |
2024-08-26 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-CD38 antistoffer og fusioner til svækket interferon alpha-2b
|
|
US11117975B2
(en)
|
2013-04-29 |
2021-09-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
|
CN105873953A
(zh)
|
2013-11-04 |
2016-08-17 |
格兰马克药品股份有限公司 |
重靶向t细胞的异源二聚免疫球蛋白的产生
|
|
US9732154B2
(en)
|
2014-02-28 |
2017-08-15 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
|
|
US9603927B2
(en)
|
2014-02-28 |
2017-03-28 |
Janssen Biotech, Inc. |
Combination therapies with anti-CD38 antibodies
|
|
TN2017000532A1
(en)
*
|
2014-03-28 |
2019-04-12 |
Xencor Inc |
Bispecific antibodies that bind to cd38 and cd3.
|
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
|
WO2015195555A1
(en)
|
2014-06-16 |
2015-12-23 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells
|
|
WO2015195556A1
(en)
|
2014-06-16 |
2015-12-23 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Blocking cd38 using anti-cd38 f(ab')2 to protect nk cells
|
|
SG11201701867SA
(en)
|
2014-09-09 |
2017-04-27 |
Janssen Biotech Inc |
Combination therapies with anti-cd38 antibodies
|
|
EA037749B1
(ru)
|
2014-10-29 |
2021-05-18 |
Тева Фармасьютикалз Острэйлиа Пти Лтд |
ВАРИАНТЫ ИНТЕРФЕРОНА 2b
|
|
WO2016067035A1
(en)
|
2014-10-29 |
2016-05-06 |
Bicycle Therapeutics Limited |
Bicyclic peptide ligands specific for mt1-mmp
|
|
MA40894A
(fr)
*
|
2014-11-04 |
2017-09-12 |
Glenmark Pharmaceuticals Sa |
Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
|
|
US11773166B2
(en)
|
2014-11-04 |
2023-10-03 |
Ichnos Sciences SA |
CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
|
|
CN107406512A
(zh)
|
2014-11-26 |
2017-11-28 |
Xencor公司 |
结合cd3和cd38的异二聚体抗体
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
BR112017011092A2
(pt)
|
2014-11-26 |
2017-12-26 |
Xencor Inc |
anticorpos heterodiméricos que ligam cd3 e antígenos de tumor
|
|
UA123697C2
(uk)
|
2014-12-04 |
2021-05-19 |
Янссен Байотек, Інк. |
Спосіб лікування гострого мієлоїдного лейкозу шляхом застосування антитіла до cd38
|
|
US10059774B2
(en)
*
|
2015-04-08 |
2018-08-28 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind CD38
|
|
ES2862708T3
(es)
|
2015-05-13 |
2021-10-07 |
Morphosys Ag |
Tratamiento del mieloma múltiple (MM)
|
|
AU2016264725B2
(en)
|
2015-05-20 |
2021-05-27 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignancies
|
|
RS60441B1
(sr)
|
2015-05-30 |
2020-07-31 |
Molecular Templates Inc |
De-imunizovane, strukture shiga toksin a podjedinice i ciljani ćelijski molekuli koji sadrže isti
|
|
PE20181323A1
(es)
|
2015-06-22 |
2018-08-14 |
Janssen Biotech Inc |
Terapias de combinacion para enfermedades malignas hematologicas con anticuerpos anti-cd38 e inhibidores de survivina
|
|
US20170044265A1
(en)
|
2015-06-24 |
2017-02-16 |
Janssen Biotech, Inc. |
Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
|
|
FI3313441T3
(fi)
|
2015-06-24 |
2024-03-28 |
Janssen Biotech Inc |
Kiinteiden kasvainten immunomodulaatio ja hoito spesifisesti cd38:aa sitovilla vasta-aineilla
|
|
SI3370770T1
(sl)
|
2015-11-03 |
2021-03-31 |
Janssen Biotech, Inc. |
Subkutane formulacije protiteles proti CD38 in njihove uporabe
|
|
US10781261B2
(en)
|
2015-11-03 |
2020-09-22 |
Janssen Biotech, Inc. |
Subcutaneous formulations of anti-CD38 antibodies and their uses
|
|
IL260750B2
(en)
|
2016-03-04 |
2024-02-01 |
Morphosys Ag |
Clinical evaluation of protein-M response in multiple myeloma
|
|
US20190233533A1
(en)
|
2016-06-28 |
2019-08-01 |
Umc Utrecht Holding B.V. |
Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
|
|
WO2018005706A1
(en)
|
2016-06-28 |
2018-01-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
|
WO2018015498A1
(en)
|
2016-07-20 |
2018-01-25 |
Hybrigenics Sa |
Combinations of inecalcitol with an anti-cd38 agent and their uses for treating cancer
|
|
US12343394B2
(en)
|
2017-06-08 |
2025-07-01 |
Black Belt Therapeutics Limited |
CD38 modulating antibody agents
|
|
NZ759835A
(en)
*
|
2017-06-08 |
2025-09-26 |
Black Belt Therapeutics Ltd |
Cd38 modulating antibody
|
|
US11191845B2
(en)
|
2017-06-20 |
2021-12-07 |
Sorrento Therapeutics, Inc. |
CD38 antibody drug conjugate
|
|
EP3645549A1
(en)
|
2017-06-26 |
2020-05-06 |
BicycleRD Limited |
Bicyclic peptide ligands with detectable moieties and uses thereof
|
|
CN111183147B
(zh)
|
2017-08-04 |
2024-07-05 |
拜斯科技术开发有限公司 |
Cd137特异性的双环肽配体
|
|
CA3072296A1
(en)
|
2017-08-16 |
2019-02-21 |
Black Belt Therapeutics Limited |
Cd38 antibody
|
|
US11542338B2
(en)
|
2017-08-16 |
2023-01-03 |
Black Belt Therapeutics Limited |
CD38 modulating antibody
|
|
CN111032693B
(zh)
|
2017-08-16 |
2023-09-26 |
黑带医疗有限公司 |
Cd38调节抗体
|
|
JP7036909B2
(ja)
*
|
2017-10-10 |
2022-03-15 |
サノフイ |
抗ｃｄ３８抗体および使用方法
|
|
EP3703749A1
(en)
|
2017-10-31 |
2020-09-09 |
Janssen Biotech, Inc. |
Methods of treating high risk multiple myeloma
|
|
WO2019094637A1
(en)
|
2017-11-08 |
2019-05-16 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-pd-1 sequences
|
|
TWI825046B
(zh)
|
2017-12-19 |
2023-12-11 |
英商拜西可泰克斯有限公司 |
Epha2特用之雙環胜肽配位基
|
|
GB201721265D0
(en)
|
2017-12-19 |
2018-01-31 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for EphA2
|
|
WO2019149743A1
(en)
|
2018-01-30 |
2019-08-08 |
Cellectis |
Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
|
|
CN110144008B
(zh)
*
|
2018-02-12 |
2021-03-19 |
杭州尚健生物技术有限公司 |
Cd38蛋白抗体及其应用
|
|
EP3755725A1
(en)
|
2018-02-23 |
2020-12-30 |
BicycleTX Limited |
Multimeric bicyclic peptide ligands
|
|
EP3773911A2
(en)
|
2018-04-04 |
2021-02-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
GB201810316D0
(en)
|
2018-06-22 |
2018-08-08 |
Bicyclerd Ltd |
Peptide ligands for binding to EphA2
|
|
IL279489B2
(en)
|
2018-06-22 |
2025-10-01 |
Bicycletx Ltd |
Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
|
|
GB201810320D0
(en)
|
2018-06-22 |
2018-08-08 |
Bicycletx Ltd |
Peptide ligands for binding to CD38
|
|
WO2020081881A2
(en)
|
2018-10-17 |
2020-04-23 |
Janssen Biotech, Inc. |
Method of providing subcutaneous administration of anti-cd38 antibodies
|
|
EP3883607A4
(en)
|
2018-11-20 |
2022-08-17 |
Janssen Biotech, Inc. |
SAFE AND EFFICIENT METHOD OF TREATMENT OF PSORIASIS WITH ANTI-IL-23 SPECIFIC ANTIBODY
|
|
GB201820325D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for psma
|
|
GB201820295D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for MT1-MMP
|
|
GB201820288D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicycle Tx Ltd |
Bicycle peptide ligaands specific for MT1-MMP
|
|
CA3122902A1
(en)
|
2018-12-14 |
2020-06-18 |
Morphosys Ag |
Antibody formulations
|
|
EP3897849A1
(en)
|
2018-12-21 |
2021-10-27 |
BicycleTx Limited |
Bicyclic peptide ligands specific for pd-l1
|
|
GB201900530D0
(en)
|
2019-01-15 |
2019-03-06 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for CD38
|
|
GB201900529D0
(en)
|
2019-01-15 |
2019-03-06 |
Bicycletx Ltd |
Bicyclic peptide ligands specific for CD38
|
|
EP3938394A1
(en)
|
2019-03-15 |
2022-01-19 |
MorphoSys AG |
Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
|
|
WO2020234834A1
(en)
|
2019-05-23 |
2020-11-26 |
Janssen Biotech, Inc. |
Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
|
|
MA56388A
(fr)
|
2019-06-27 |
2022-05-04 |
Crispr Therapeutics Ag |
Utilisation de lymphocytes t récepteurs d'antigènes chimériques et d'inhibiteurs de cellules nk pour le traitement du cancer
|
|
BR112021026832A2
(pt)
|
2019-07-02 |
2022-05-10 |
Hutchinson Fred Cancer Res |
Vetores ad35 recombinantes e aprimoramentos da terapia gênica relacionada
|
|
TWI862640B
(zh)
|
2019-07-30 |
2024-11-21 |
英商拜西可泰克斯有限公司 |
異質雙環肽複合物
|
|
CN115362171A
(zh)
*
|
2020-03-31 |
2022-11-18 |
百奥泰生物制药股份有限公司 |
用于治疗冠状病毒的抗体、融合蛋白及其应用
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
MX2022014430A
(es)
|
2020-05-21 |
2023-02-22 |
Janssen Biotech Inc |
Método para tratar la enfermedad inflamatoria del intestino con una terapia de combinación de anticuerpos para il-23 y tnf alfa.
|
|
EP4171585A1
(en)
|
2020-06-26 |
2023-05-03 |
CRISPR Therapeutics AG |
Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
|
|
CN114075283A
(zh)
|
2020-08-12 |
2022-02-22 |
三生国健药业（上海）股份有限公司 |
结合人cd38的抗体、其制备方法和用途
|
|
CN114195893A
(zh)
*
|
2020-09-17 |
2022-03-18 |
百奥泰生物制药股份有限公司 |
抗整联蛋白抗体或抗原结合片段及其应用
|
|
GB202016331D0
(en)
|
2020-10-15 |
2020-12-02 |
Bicyclerd Ltd |
Bicyclic peptide ligand drug conjugates
|
|
WO2022137186A1
(en)
|
2020-12-23 |
2022-06-30 |
Crispr Therapeutics Ag |
Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor
|
|
WO2022152823A1
(en)
|
2021-01-14 |
2022-07-21 |
Morphosys Ag |
Anti-cd38 antibodies and their uses
|
|
US20220275090A1
(en)
|
2021-02-22 |
2022-09-01 |
Janssen Biotech, Inc. |
Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
|
|
TW202302642A
(zh)
|
2021-03-01 |
2023-01-16 |
德商莫菲西斯公司 |
用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
|
|
EP4305067A1
(en)
|
2021-03-09 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
|
JP2024509274A
(ja)
|
2021-03-10 |
2024-02-29 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
|
|
US20220378829A1
(en)
|
2021-05-12 |
2022-12-01 |
Crispr Therapeutics Ag |
Genetically engineered immune cells targeting cd70 for use in treating solid tumors
|
|
WO2022238962A1
(en)
|
2021-05-12 |
2022-11-17 |
Crispr Therapeutics Ag |
Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignancies
|
|
TW202321303A
(zh)
|
2021-07-19 |
2023-06-01 |
德商莫菲西斯公司 |
抗pla2r自體抗體媒介膜性腎病變之治療
|
|
JP2024540304A
(ja)
|
2021-11-03 |
2024-10-31 |
ヤンセン バイオテツク，インコーポレーテツド |
抗ｃｄ３８抗体による治療におけるコルチコステロイドの減少
|
|
WO2023098813A1
(en)
*
|
2021-12-03 |
2023-06-08 |
Nanjing Leads Biolabs Co., Ltd. |
Antibodies binding cd38 and uses thereof
|
|
EP4472740A1
(en)
|
2022-01-31 |
2024-12-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd38 as a biomarker and biotarget in t-cell lymphomas
|
|
TW202423970A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
|